Skip to content

Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)

Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04863872
Acronym
PHT2
Enrollment
259
Registered
2021-04-28
Start date
2022-01-26
Completion date
2024-06-21
Last updated
2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Hypoglycemia

Keywords

Hypoglycemia, Self-management, Diabetes Mellitus, Type 2, Patient Education

Brief summary

Severe hypoglycemia is the most feared complication of medications used to lower blood glucose levels in patients with diabetes. Severe hypoglycemia, defined as plasma glucose low enough to require assistance, has been linked to poor health-related quality of life, emotional and interpersonal challenges, car accidents, serious falls, cardiovascular events, dementia, and death. Older adults with type 2 diabetes are particularly vulnerable to the complications of severe hypoglycemia. Each year, approximately 11% of patients with type 2 diabetes self-report severe hypoglycemia episodes. An estimated 14% of emergency hospitalizations of older Americans for adverse drug events implicate insulin and 11% implicate oral hypoglycemic agents. One in four diabetes-related hospital admissions is for hypoglycemia. This study will compare two ways to reduce severe hypoglycemia in people with type 2 diabetes. The two methods to be compared are: 1. Proactive care management. This will be a nurse outreach call which is similar to the usual care that people with type 2 diabetes get to reduce their risk of severe hypoglycemia, but given in advance rather than in response to a recent severe hypoglycemia event. 2. The same proactive care management (nurse outreach call) plus enrollment in MyHC-T2D, a health education program aimed at improving awareness of hypoglycemia and preventing severe hypoglycemia. This program has been shown to reduce severe hypoglycemia in people with type 1 diabetes but has not been tested in persons with type 2. Our hypothesis is that proactive care management plus MyHC-T2D will be more effective than proactive care management alone at preventing self-reported severe hypoglycemia in adults with type 2 diabetes at high risk for severe hypoglycemia. The primary outcome will be measured using surveys at the beginning of the study and 14-months later.

Detailed description

This study is a two-arm, individually-randomized, comparative effectiveness study of two evidence-based approaches to preventing severe hypoglycemia. We will identify participants using Electronic Health Record (EHR) data. They will be identified for potential recruitment if they are age 18 and older, diagnosed with type 2 diabetes, receiving primary care at Kaiser Permanente Washington and have a current prescription for insulin or identified using an EHR-based risk stratification tool as being at intermediate to high risk for a severe hypoglycemia event. Within this population, we will recruit participants who either have impaired awareness of hypoglycemia or self-report a severe hypoglycemia event in the prior 12 months. Participants must be members of Kaiser Permanente Washington and identified by the study. Following randomization, we will compare patients who receive proactive care management from nurses to patients receiving proactive care management plus MyHC-T2D, a structured educational intervention that reduces the frequency of severe hypoglycemia in individuals with type 1 diabetes. In both groups, we will use proactive care management to assess and provide evidence-based care for impaired awareness of hypoglycemia and other potential contributors to severe hypoglycemia risk. Our primary outcome is participant-reported severe hypoglycemia, to capture all events, including those not involving clinical care. We will also examine biochemical measures of hypoglycemia measured using continuous glucose monitoring (CGM), participant-reported hypoglycemia awareness, fear of hypoglycemia, and emergency department visits and hospitalizations for severe hypoglycemia. We will conduct a process evaluation to assess the fidelity of implementation and clarify the causal pathway.

Interventions

OTHERProactive Care Management

Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.

BEHAVIORALMyHC-T2D education program

Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.

Sponsors

Patient-Centered Outcomes Research Institute
CollaboratorOTHER
Kaiser Permanente
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Two-arm randomized controlled trial comparing the effectiveness of 2 approaches for preventing severe hypoglycemia among participants with type 2 diabetes who are at risk for severe hypoglycemia. Participants were randomly assigned to one of two interventions: 1) Proactive Care Management, consisting of outreach from Kaiser Permanente Washington (KPWA) nurses using standard KPWA clinical tools; 2) the same Proactive Care Management plus MyHC-T2D, a structured educational intervention.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Diagnosed with type 2 diabetes * Receiving primary care at Kaiser Permanente Washington (KPWA) * Enrollment in KPWA at baseline and planning to stay with a KPWA health plan for the next 6 months * Current prescription for insulin or at intermediate to high risk for severe hypoglycemia episode using the hypoglycemia risk stratification tool developed by Karter et. al. * History of severe hypoglycemia in the prior 12 months or impaired awareness of hypoglycemia

Exclusion criteria

* Inability to give informed consent * Unable to speak or read English * Inability or unwillingness to attend online or telephone educational sessions, follow up calls, or to complete outcome assessments * Prior diagnosis of dementia, severe psychiatric conditions with psychosis, severe cognitive impairment * Currently living in a nursing home or under hospice care * Current use at baseline of Continuous Glucose Monitor * Pregnant or planning to become pregnant

Design outcomes

Primary

MeasureTime frameDescription
Self-reported Severe Hypoglycemia14 monthsAny self-reported severe hypoglycemia in prior 12 months

Countries

United States

Participant flow

Recruitment details

Participants were enrolled based on identification from the Electronic Medical Record followed by outreach and telephone screening from January 2022 to January 2023. The first participant was enrolled on January 26, 2022 and the last participant was enrolled in January 2023.

Participants by arm

ArmCount
Proactive Care Management
Proactive Care Management: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
129
Proactive Care Management + MyHC-T2D Education Program
Proactive Care Management: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated. MyHC-T2D education program: Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
130
Total259

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath52
Overall StudyLost to Follow-up21
Overall StudyWithdrawal by Subject415

Baseline characteristics

CharacteristicProactive Care ManagementProactive Care Management + MyHC-T2D Education ProgramTotal
Age, Customized
Age, categorical
Age 75 years and older
37 Participants38 Participants75 Participants
Age, Customized
Age, categorical
Age less than 75 years
92 Participants92 Participants184 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants8 Participants13 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
124 Participants122 Participants246 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Hypoglycemic risk score
High
9 Participants8 Participants17 Participants
Hypoglycemic risk score
Low
60 Participants61 Participants121 Participants
Hypoglycemic risk score
Moderate
60 Participants61 Participants121 Participants
Impaired awareness of hypoglycemia
Impaired awareness
104 Participants118 Participants222 Participants
Impaired awareness of hypoglycemia
Missing
1 Participants0 Participants1 Participants
Impaired awareness of hypoglycemia
No impaired awareness
24 Participants12 Participants36 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Asian
7 Participants7 Participants14 Participants
Race (NIH/OMB)
Black or African American
13 Participants7 Participants20 Participants
Race (NIH/OMB)
More than one race
5 Participants6 Participants11 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2 Participants1 Participants3 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants6 Participants8 Participants
Race (NIH/OMB)
White
99 Participants102 Participants201 Participants
Self report of any severe hypoglycemia in past 12 months
Missing
0 Participants1 Participants1 Participants
Self report of any severe hypoglycemia in past 12 months
One or more
44 Participants32 Participants76 Participants
Self report of any severe hypoglycemia in past 12 months
Zero
85 Participants97 Participants182 Participants
Sex: Female, Male
Female
76 Participants81 Participants157 Participants
Sex: Female, Male
Male
53 Participants49 Participants102 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
5 / 1292 / 130
other
Total, other adverse events
39 / 12954 / 130
serious
Total, serious adverse events
46 / 12956 / 130

Outcome results

Primary

Self-reported Severe Hypoglycemia

Any self-reported severe hypoglycemia in prior 12 months

Time frame: 14 months

Population: Participants included who completed the 14-month survey.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Proactive Care ManagementSelf-reported Severe HypoglycemiaZero99 Participants
Proactive Care ManagementSelf-reported Severe HypoglycemiaOne or more19 Participants
Proactive Care Management + MyHC-T2D Education ProgramSelf-reported Severe HypoglycemiaZero99 Participants
Proactive Care Management + MyHC-T2D Education ProgramSelf-reported Severe HypoglycemiaOne or more13 Participants
p-value: 0.2795% CI: [0.39, 1.3]Poisson regression

Source: ClinicalTrials.gov · Data processed: May 14, 2026